PL EN


Preferences help
enabled [disable] Abstract
Number of results
2013 | 60 | 2 | 195-198
Article title

Development of a new, simple and cost-effective diagnostic tool for genetic screening of hereditary colorectal cancer - the DNA microarray assay

Content
Title variants
Languages of publication
EN
Abstracts
EN
Detection of mutations in families with a hereditary predisposition to colon cancer gives an opportunity to precisely define the high-risk group. 36 patients operated on for colon cancer, with familiar prevalence of this malignancy, were investigated using the DNA microarrays method with the potential detection of 170 mutations in MLH1, MSH2, MSH6, CHEK2, and NOD2 genes. In microarrays analysis of DNA in 9 patients (25% of the investigated group), 6 different mutations were found. The effectiveness of genetic screening using the microarray method is comparable to the effectiveness of other, much more expensive and time-consuming methods.
Keywords
Publisher

Year
Volume
60
Issue
2
Pages
195-198
Physical description
Dates
published
2013
received
2012-12-31
revised
2013-04-14
accepted
2013-06-03
(unknown)
2013-06-06
Contributors
author
  • Regional Specialistic Hospital, Słupsk, Department of General, Vascular and Oncologic, Surgery, Słupsk, Poland
  • Department of General Surgery, Oncologic Gastroenterologic Surgery and Plastic Surgery, Poznań University of Medical Sciences, Poznań, Poland
  • Medical Genetic Laboratory, DNA Research Center Ltd., Poznań, Poland
author
  • Medical Genetic Laboratory, DNA Research Center Ltd., Poznań, Poland
  • Department of Rehabilitation, Józef Piłsudski University of Physical Education in Warsaw, Warsaw, Poland
  • Department of General Surgery, Oncologic Gastroenterologic Surgery and Plastic Surgery, Poznań University of Medical Sciences, Poznań, Poland
  • Department of General Surgery, Oncologic Gastroenterologic Surgery and Plastic Surgery, Poznań University of Medical Sciences, Poznań, Poland
  • Department of General Surgery, Oncologic Gastroenterologic Surgery and Plastic Surgery, Poznań University of Medical Sciences, Poznań, Poland
  • Department of General Surgery, Oncologic Gastroenterologic Surgery and Plastic Surgery, Poznań University of Medical Sciences, Poznań, Poland
author
  • Department of General Surgery, Oncologic Gastroenterologic Surgery and Plastic Surgery, Poznań University of Medical Sciences, Poznań, Poland
  • Medical Genetic Laboratory, DNA Research Center Ltd., Poznań, Poland
  • Department of Clinical Pathomorphology, Poznań University of Medical Sciences, Poznań, Poland
  • Department of Cancer Immunology, Poznań University of Medical Sciences, Greater Poland Cancer Center, Poznań, Poland
  • Laboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznań, Poland
author
  • Department of General Surgery, Oncologic Gastroenterologic Surgery and Plastic Surgery, Poznań University of Medical Sciences, Poznań, Poland
  • Medical Genetic Laboratory, DNA Research Center Ltd., Poznań, Poland
References
  • Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME, Campbell H, Dunlop MG (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354: 2751-2763.
  • Bleiker EM, Menko FH, Taal BG, Kluijt I, Wever LD, Gerritsma MA, Vasen HF, Aaronson NK (2005) Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology 128: 280-287.
  • Bonis PA, Trikalinos TA, Chung M, Chew P, Ip S, DeVine DA, Lau J (2007) Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep) 150: 1-180.
  • Brodersen NH, Sutton S, Goff S, Hodgson SV, Thomas HJ (2004) Anticipated reactions to genetic testing for hereditary non-polyposis colorectal cancer susceptibility. Clin Genet 66: 437-444.
  • Chagovetz A, Blair S (2009) Real-time DNA microarrays: reality check. Biochem Soc Trans 37: 471-475.
  • Chung DC, Rustgi AK (2003) The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 138: 560-570.
  • Dove-Edwin I, Sasieni P, Adams J, Thomas HJ (2005) Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 331: 1047.
  • Egeland RD, Southern EM (2005) Electrochemically directed synthesis of oligonucleotides for DNA microarray fabrication. Nucleic Acids Res 33: e125.
  • Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2009) Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11: 35-41.
  • Fu L, Sheng JQ, Sun ZQ, Han M, Huang JS, Mu H, Han WL, Niu HL, Li AQ, Wu ZT, Li SR (2008) Mutation of hMLH1 and hMSH2 genes in hereditary nonpolyposis colorectal cancer: analysis of 76 probands. Zhonghua Yi Xue Za Zhi 88: 1983-1985 (in Chinese).
  • Geary J, Thomas HJ, Mackay J, Dorkins H, Barwell J, Hodgson SV (2007) The management of families affected by hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 6: 13-19.
  • Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352: 1851-1860.
  • Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, de la Chapelle A, Mecklin JP (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118: 829-834.
  • Kauff ND (2007) How should women with early-onset endometrial cancer be evaluated for lynch syndrome? J Clin Oncol 25: 5143-5146.
  • Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA (2011) Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 155: 69-79.
  • Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR (2007) Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25: 5158-5164.
  • Lynch HT, Jascur T, Lanspa S, Boland CR (2010) Making sense of missense in Lynch syndrome: the clinical perspective. Cancer Prev Res (Phila) 3: 1371-1374.
  • Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76: 1-18.
  • Niessen RC, Berends MJ, Wu Y, Sijmons RH, Hollema H, Ligtenberg MJ, de Walle HE, de Vries EG, Karrenbeld A, Buys CH, van der Zee AG, Hofstra RM, Kleibeuker JH (2006) Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer. Gut 55: 1781-1788.
  • Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11: 42-65.
  • Perez-Cabornero L, Velasco E, Infante M, Sanz D, Lastra E, Hernández L, Miner C, Duran M (2009) A new strategy to screen MMR genes in Lynch Syndrome: HA-CAE, MLPA and RT-PCR. Eur J Cancer 45: 1485-1493.
  • Rees G, Martin PR, Macrae FA (2008) Screening participation in individuals with a family history of colorectal cancer: a review. Eur J Cancer Care 17: 221-232.
  • Schulze A, Downward J (2001) Navigating gene expression using microarrays - a technology review. Nature Cell Biol 3: E190-E195.
  • Smyth GK, Yang YH, Speed T (2003) Statistical issues in cDNA microarray data analysis; functional genomics: methods and protocols. Methods Mol Biol 224: 111-136.
  • Spaepen M, Vankeirsbilck B, Van Opstal S, Tejpar S, Van Cutsem E, Geboes K, Legius E, Matthijs G (2006) Germline mutations of the hMLH1 and hMSH2 mismatch repair genes in Belgian hereditary nonpolyposis colon cancer (HNPCC) patients. Fam Cancer 5: 179-89.
  • Tang R, Hsiung C, Wang JY, Lai CH, Chien HT, Chiu LL, Liu CT, Chen HH, Wang HM, Chen SX, Hsieh LL (2009) TCOG HNPCC Consortium.: Germ line MLH1 and MSH2 mutations in Taiwanese Lynch syndrome families: characterization of a founder genomic mutation in the MLH1 gene. Clin Genet 75: 334-345.
  • van Roon EH, de Miranda NF, van Nieuwenhuizen MP, de Meijer EJ, van Puijenbroek M, Yan PS, Huang TH, van Wezel T, Morreau H, Boer JM (2011) Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer. Eur J Hum Genet 19: 307-312.
  • Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34: 424-425.
  • Wadlow R, Ramaswamy S (2005) DNA microarrays in clinical cancer research. Curr Mol Med 5: 111-120.
  • Wang VW, Koh PK, Chow WL, Lim JF (2012) Predictive genetic testing of first degree relatives of mutation carriers is a cost-effective strategy in preventing hereditary non-polyposis colorectal cancer in Singapore. Fam Cancer 11: 279-289.
  • Watson P, Narod SA, Fodde R, Wagner A, Lynch JF, Tinley ST, Snyder CL, Coronel SA, Riley B, Kinarsky Y, Lynch HT (2003) Carrier risk status changes resulting from mutation testing in hereditary nonpolyposis colorectal cancer and hereditary breast-ovarian cancer. J Med Genet 40: 591-596.
  • Wijnen JT, Vasen HF, Khan PM, Zwinderman AH, van der Klift H, Mulder A, Tops C, Møller P, Fodde R (1998) Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 339: 511-518.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv60p195kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.